Volume | 10,589 |
|
|||||
News | - | ||||||
Day High | 3.825 | Low High |
|||||
Day Low | 3.53 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
GT Biopharma Inc | GTBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.74 | 3.53 | 3.825 | 3.65 | 3.78 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
118 | 10,589 | $ 3.65 | $ 38,607 | - | 3.52 - 16.11 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:23:45 | 10 | $ 3.53 | USD |
GT Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.04M | 1.38M | - | 0 | -7.6M | -5.50 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
GT Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GTBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.665 | 4.1815 | 3.53 | 3.77 | 5,187 | -0.015 | -0.41% |
1 Month | 4.35 | 4.81 | 3.53 | 4.13 | 7,363 | -0.70 | -16.09% |
3 Months | 6.618 | 7.02 | 3.52 | 5.21 | 32,080 | -2.97 | -44.85% |
6 Months | 6.915 | 9.90 | 3.52 | 6.89 | 87,226 | -3.27 | -47.22% |
1 Year | 11.748 | 16.11 | 3.52 | 8.68 | 232,548 | -8.10 | -68.93% |
3 Years | 300.00 | 591.993 | 3.52 | 141.16 | 217,313 | -296.35 | -98.78% |
5 Years | 165.00 | 591.993 | 3.52 | 154.36 | 246,088 | -161.35 | -97.79% |
GT Biopharma Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. |